Updated on 3 September 2026
NANOCOMBO project: exploring opportunities in drug repurposing associated with multi-drug combination
CEO at THERIOPHARM
Wavre, Belgium
About
Drug combination is a very powerful approach to design and tailor efficient treatment . Our nanodrop technology have the same size than a coronavirus and can be loaded with targeting synthons (RGD peptide, for example).
We are looking for academics/SMEs interested in exploring with us our NANOCOMBO approach. Our technology is suitable for any administration route in any therapeutic field.
We currently develop a drug repurposing approach applied to cancer solid tumor treatment (Glioblastoma) in murine preclinical models.
We seek for experts in organoids, PDX models, PK/PD, imaging, digital twins , to extend the strategy to other types of cancer.
Stage
- Ideation - identifying the project idea / Concept note/ Idea
Topic
- Digital and Smart Health
Call
- HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses
- HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses
- HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials
- HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
- HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases
- HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
- HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
- HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine
- HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Attached files
Organisation
Similar opportunities
Project cooperation
- HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
Paola Rizzo
Director at Interagens s.r.l.
Rome, Italy
Project cooperation
- HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic non-communicable diseases in children and young people (GACD)
Paola Rizzo
Director at Interagens s.r.l.
Rome, Italy
Project cooperation
- Digital and Smart Health
- Consortium/Co-ordinator seeks Partner
- Drafting - writing the project proposal
- HORIZON-CL4-2027-04-DIGITAL-EMERGING-06: International cooperation in AI
- HORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcare
- HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases
- HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion HO
- HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases
Andras Hazai
Managing Director at ASAcrew
Budapest, Hungary